Answers are grounded in this paper and cite their sources.
Compared with standard paclitaxel, Genexol-PM demonstrated non-inferior and even superior clinical efficacy with a manageable safety profile in patients with metastatic breast cancer.
No takes yet. Share an insight, caveat, or question.
Park et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: